1. 122TiPGeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (13th May 2019) Authors: Loibl, S; Jackisch, C; Rastogi, P; Seiler, S; Lucas, P C; Denkert, C; Costantino, J; Nekljudova, V; Wolmark, N; Geyer, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗